Related Experiment Video

Updated: May 20, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Metastatic melanoma and vemurafenib: novel approaches

Ramon Andrade De Mello1

  • 1Department of Medical Oncology, Portuguese Oncology Institute and.

Rare Tumors
|July 25, 2012
PubMed

Insights

Metastatic melanoma treatment is challenging. Vemurafenib, a BRAF kinase inhibitor targeting the V600 mutation, shows promise for metastatic melanoma (MM) patients, though concerns remain.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Metastatic melanoma (MM) poses a significant global treatment challenge.
  • Dacarbazine, the standard first-line chemotherapy, exhibits poor response rates.
  • The BRAF V600 mutation is implicated in 40-60% of melanoma cases.

Purpose of the Study:

  • To review the efficacy of vemurafenib in treating metastatic melanoma.
  • To highlight emerging concerns regarding vemurafenib therapy.

Main Methods:

  • Review of clinical trial data (Phase I-III) for vemurafenib.
  • Analysis of vemurafenib's mechanism of action as a BRAF kinase inhibitor.

Main Results:

  • Vemurafenib demonstrated impressive results in clinical trials for MM.
  • The drug targets the specific BRAF V600 mutation prevalent in melanoma.

Conclusions:

  • Vemurafenib represents a significant advancement in MM treatment.
  • Further evaluation is necessary to address potential concerns associated with vemurafenib.
Keywords:
BRAF V600 mutationdabrafenibmalignant melanomametastatic diseaseskin cancer.vemurafenib

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.